Literature DB >> 16144913

Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.

Daniela Bonofiglio1, Sabrina Gabriele, Saveria Aquila, Stefania Catalano, Mariaelena Gentile, Emilia Middea, Francesca Giordano, Sebastiano Andò.   

Abstract

PURPOSE: The molecular mechanisms involved in the repressive effects exerted by estrogen receptors (ER) on peroxisome proliferator-activated receptor (PPAR) gamma-mediated transcriptional activity remain to be elucidated. The aim of the present study was to provide new insight into the crosstalk between ERalpha and PPARgamma pathways in breast cancer cells. EXPERIMENTAL
DESIGN: Using MCF7 and HeLa cells as model systems, we did transient transfections and electrophoretic mobility shift assay and chromatin immunoprecipitation studies to evaluate the ability of ERalpha to influence PPAR response element-mediated transcription. A possible direct interaction between ERalpha and PPARgamma was ascertained by co-immunoprecipitation assay, whereas their modulatory role in the phosphatidylinositol 3-kinase (PI3K)/AKT pathway was evaluated by determining PI3K activity and AKT phosphorylation. As a biological counterpart, we investigated the growth response to the cognate ligands of both receptors in hormone-dependent MCF7 breast cancer cells.
RESULTS: Our data show for the first time that ERalpha binds to PPAR response element and represses its transactivation. Moreover, we have documented the physical and functional interactions of ERalpha and PPARgamma, which also involve the p85 regulatory subunit of PI3K. Interestingly, ERalpha and PPARgamma pathways have an opposite effect on the regulation of the PI3K/AKT transduction cascade, explaining, at least in part, the divergent response exerted by the cognate ligands 17beta-estradiol and BRL49653 on MCF7 cell proliferation.
CONCLUSION: ERalpha physically associates with PPARgamma and functionally interferes with PPARgamma signaling. This crosstalk could be taken into account in setting new pharmacologic strategies for breast cancer disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144913     DOI: 10.1158/1078-0432.CCR-04-2453

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  64 in total

1.  Estrogen deficiency does not decrease the in vitro osteogenic potential of rat adipose-derived mesenchymal stem cells.

Authors:  Francesca Veronesi; Stefania Pagani; Elena Della Bella; Gianluca Giavaresi; Milena Fini
Journal:  Age (Dordr)       Date:  2014-04-01

2.  Cellular and molecular effects of thiazolidinediones on bone cells: a review.

Authors:  Guillaume Mabilleau; Daniel Chappard; Michel F Baslé
Journal:  Int J Biochem Mol Biol       Date:  2011-06-20

3.  TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction.

Authors:  Ashok Kumar; Ming Ruan; Kari Clifton; Farhan Syed; Sundeep Khosla; Merry Jo Oursler
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

4.  Is there an estrogenic component in the metabolic syndrome?

Authors:  S Starcke; G Vollmer
Journal:  Genes Nutr       Date:  2006-09       Impact factor: 5.523

5.  Intracellular receptor regulation of adipose metabolism by the isoflavone genistein.

Authors:  Isabella Zanella; Diego Di Lorenzo
Journal:  Eur J Nutr       Date:  2015-04       Impact factor: 5.614

6.  Dietary tocopherols inhibit cell proliferation, regulate expression of ERα, PPARγ, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia.

Authors:  Amanda K Smolarek; Jae Young So; Paul E Thomas; Hong Jin Lee; Shiby Paul; Anne Dombrowski; Chung-Xiou Wang; Constance Lay-Lay Saw; Tin Oo Khor; Ah-Ng Tony Kong; Kenneth Reuhl; Mao-Jung Lee; Chung S Yang; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

7.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

8.  Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Authors:  Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

9.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

10.  PPARgamma, PTEN, and the Fight against Cancer.

Authors:  Rosemary E Teresi; Kristin A Waite
Journal:  PPAR Res       Date:  2008-12-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.